Personalized mRNA Therapy Shows Positive Phase 3 Results in Melanoma
Merck and Moderna report positive Phase 3 results for their personalized mRNA…
New Access Strategy Announced for Investigational Monthly HIV Prevention Pill
Merck has announced an early access strategy for its investigational once-monthly HIV…
ADAP Crisis Task Force Strikes Deal to Widen Access to New HIV Pill
Merck has partnered with the ADAP Crisis Task Force to expand access…
Merck launches online symptom checker to promote early detection of colorectal cancer in the Gulf
Merck has launched an online Symptom Checker to help raise awareness of…
Merck Launches ChemiSphereยฎ App
Merck, a leading science and technology company, announced the launch of the…
WHO and ESPEN Conduct Technical Mission to Strengthen Schistosomiasis Medicine Management in Zimbabwe
World Health Organization (WHO)'s Regional Office for Africa (AFRO), through the Expanded…
Merck to Host Investor Event Highlighting Advances in HIV Treatment and Prevention Pipeline
Merck, known as MSD outside of the United States and Canada, announced…
Two Days to Go, London Biotechnology Show 2025 Gears Up to Spotlight Industry Pioneers, DisruptiveTech, Emerging Innovators
In just two days, the second edition of the London Biotechnology Show…
Merck enters into exclusive global license agreement with Hansoh Pharma
December 2024- Merck, known as MSD outside of the United States and…
Merck to acquire B-Cell depletion therapy from Curon Biopharmaceutical
Rahway- August 2024- Merck, known as MSD outside of the United States…
